Mao-A Inhibition By Metaxalone Reverts Il-1 Beta-Induced Inflammatory Phenotype In Microglial Cells
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES(2021)
摘要
Experimental and clinical studies have suggested that several neurological disorders are associated with the occurrence of central nervous system neuroinflammation. Metaxalone is an FDA-approved muscle relaxant that has been reported to inhibit monoamine oxidase A (MAO-A). The aim of this study was to investigate whether metaxalone might exert antioxidant and anti-inflammatory effects in HMC3 microglial cells. An inflammatory phenotype was induced in HMC3 microglial cells through stimulation with interleukin-1 beta (IL-1 beta). Control cells and IL-1 beta-stimulated cells were subsequently treated with metaxalone (10, 20, and 40 mu M) for six hours. IL-1 beta stimulated the release of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), but reduced the anti-inflammatory cytokine interleukin-13 (IL-13). The upstream signal consisted of an increased priming of nuclear factor-kB (NF-kB), blunted peroxisome proliferator-activated receptor gamma (PPAR gamma), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha) expression. IL-1 beta also augmented MAO-A expression/activity and malondialdehyde levels and decreased Nrf2 mRNA expression and protein levels. Metaxalone decreased MAO-A activity and expression, reduced NF-kB, TNF-alpha, and IL-6, enhanced IL-13, and also increased PPAR gamma, PGC-1 alpha, and Nrf2 expression. The present experimental study suggests that metaxalone has potential for the treatment of several neurological disorders associated with neuroinflammation.
更多查看译文
关键词
neuroinflammation, microglia, metaxalone, MAO-A inhibition, antioxidant activity
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要